Early safety check for hepatitis b drug in people with liver problems
NCT ID NCT07342868
Summary
This early-stage study aims to understand how a new hepatitis B drug is processed in people with moderate liver impairment compared to those with normal liver function. It involves 16 participants who will receive a single dose of the drug. The main goal is to measure drug levels in the blood and check for safety issues, not to treat hepatitis B.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPAITITIS B INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.